BeyondSpring Inc. — FY 2017 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2017. This is an annual report, not a standalone 2017 fourth-quarter report. Filed April 3, 2018. Financial statements are audited and prepared under U.S. GAAP; amounts below are U.S. dollars unless noted.
Business context
BeyondSpring is a clinical-stage biopharmaceutical company developing cancer therapies. It had no approved products and generated no product revenue. Its lead candidate, Plinabulin, was in late-stage trials for chemotherapy-induced neutropenia (CIN) and advanced non-small cell lung cancer (NSCLC), with additional early-stage immuno-oncology programs. The company owns Plinabulin rights globally except in China, where its subsidiary owns the rights and BeyondSpring holds a 60% interest.
Financial performance and position
| Metric | FY 2017 / Dec. 31, 2017 | FY 2016 / Dec. 31, 2016 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $88.9 million | $10.4 million |
| General and administrative expense | $9.1 million | $1.9 million |
| Operating loss | $98.0 million | $12.4 million |
| Net loss | $96.4 million | $12.5 million |
| Net loss attributable to BeyondSpring | $91.8 million | $12.0 million |
| Basic and diluted loss per share | $4.40 | $0.75 |
| Cash and cash equivalents | $27.5 million | $11.7 million |
| Short-term investments | $3.1 million | $0 |
| Total assets | $32.8 million | $14.9 million |
| Total liabilities | $4.8 million | $2.6 million |
| Total equity | $28.0 million | $12.3 million |
Operating cash outflow was $28.8 million, compared with $13.7 million in 2016. Investing activities used $3.2 million, principally for a one-year deposit; financing activities provided $47.7 million, mainly from the March 2017 IPO and concurrent private placement. The filing reports no revenue-based margins; they are not meaningful for a pre-commercial company. No material interest-bearing debt was reported on the year-end balance sheet.
Material changes and unusual items
- Net loss rose by $83.8 million year over year, driven largely by higher R&D and public-company costs.
- FY 2017 R&D included a $42.3 million non-cash charge for Plinabulin patent rights, settled by issuing 2,112,963 shares to Nereus Trust. This issuance terminated the related royalty arrangement.
- Share-based compensation was $22.7 million in 2017, versus none reported in 2016. The filing identifies $17.8 million in R&D and $4.9 million in G&A.
- BeyondSpring received approximately $0.9 million in government grants and reported a net foreign-exchange gain of $0.6 million.
- The company raised approximately $47.2 million net from its 2017 IPO and concurrent private placement. Year-end ordinary shares outstanding were 22,530,702.
Outlook, risks and contingencies
- Management expected continued substantial losses, negative operating cash flows and increasing R&D spending; additional financing would be needed to complete trials and support commercialization. Equity financing could dilute shareholders, while debt or partnering could impose restrictions or require giving up rights.
- Management stated that year-end cash and short-term investments of $30.6 million were expected to fund operations for at least 12 months from the filing. Separately, the notes describe a March 2018 cost-reduction plan, including deferring some projects, that management expected would extend resources into the second quarter of 2019; the founders also agreed to provide financial support. These are management expectations, not assured funding.
- Clinical milestones were contingent on positive results: interim NSCLC Study 103 data were expected in late 2018 or early 2019, with final data in 2020; CIN Studies 105 and 106 were expected to report final results in 2019. The company planned to seek conditional or accelerated Chinese approvals, and later U.S. approvals, if results supported applications. Timelines and approvals were uncertain.
- Key efficacy risk: the earlier Study 101 did not meet its primary overall-survival endpoint; favorable NSCLC survival findings came from a small, post hoc subset and were not statistically significant. The later pivotal trials could fail, require additional studies, or produce results regulators consider insufficient.
- Other material risks include dependence on Plinabulin, no commercial sales or sales infrastructure, reliance on CROs and contract manufacturers, and sole-source reliance on BASF for Solutol in the current formulation. China-related regulatory, foreign-exchange, cash-repatriation and ownership risks also apply; BeyondSpring owns only 60% of the Chinese rights-holding subsidiary.
- The company reported a prior material weakness in financial reporting controls and said it was remediated as of December 31, 2017; management assessed disclosure controls and internal control over financial reporting as effective. The auditor did not attest to internal control effectiveness. The audit opinion on the financial statements was unqualified.
- No material litigation was reported. Operating lease commitments at year-end were $66,000, all due within one year. The company did not expect to pay dividends in the foreseeable future.
Most important facts for investors to verify
- Updated cash, burn rate and financing runway, including whether founder support is available and whether the March 2018 cost reductions were implemented.
- Enrollment, interim and final results for Studies 103, 105 and 106, especially primary endpoints, safety, and whether trial findings support regulatory submissions.
- Whether regulators accept the proposed accelerated/conditional China approval path and the planned trial data for U.S. filings.
- Manufacturing supply continuity, particularly BASF’s Solutol supply and the company’s ability to scale production.
- Future share issuance, equity-plan dilution, and the implications of the 60% ownership of the China subsidiary and related-party interests.